Other immune inhibitory mechanisms may be operating in conjunction with or alongside PD-1/PD-L1 inhibition in these resistant patients, offering novel immunological targets that could potentially increase the efficacy of cancer immunotherapy [94]. The gene discussed is PDCD1; the disease is cancer.